PT2663579T - Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização - Google Patents

Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização

Info

Publication number
PT2663579T
PT2663579T PT127347334T PT12734733T PT2663579T PT 2663579 T PT2663579 T PT 2663579T PT 127347334 T PT127347334 T PT 127347334T PT 12734733 T PT12734733 T PT 12734733T PT 2663579 T PT2663579 T PT 2663579T
Authority
PT
Portugal
Prior art keywords
protein
methods
same
antibodies against
therapeutic antibodies
Prior art date
Application number
PT127347334T
Other languages
English (en)
Inventor
J Kipps Thomas
F Widhopf Ii George
Cui Bing
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46507696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2663579(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of PT2663579T publication Critical patent/PT2663579T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PT127347334T 2011-01-14 2012-01-13 Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização PT2663579T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161433043P 2011-01-14 2011-01-14

Publications (1)

Publication Number Publication Date
PT2663579T true PT2663579T (pt) 2017-07-28

Family

ID=46507696

Family Applications (2)

Application Number Title Priority Date Filing Date
PT127347334T PT2663579T (pt) 2011-01-14 2012-01-13 Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
PT191929736T PT3604339T (pt) 2011-01-14 2012-01-13 Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT191929736T PT3604339T (pt) 2011-01-14 2012-01-13 Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos

Country Status (9)

Country Link
US (7) US9217040B2 (pt)
EP (4) EP3885366A3 (pt)
CA (3) CA3027071A1 (pt)
DK (3) DK3604339T3 (pt)
ES (3) ES2634098T3 (pt)
HU (2) HUE035281T2 (pt)
PL (2) PL3604339T3 (pt)
PT (2) PT2663579T (pt)
WO (1) WO2012097313A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011079902A2 (en) 2009-12-18 2011-07-07 Biolnvent International Ab Biological materials and uses thereof
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
CN104662044B (zh) * 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
JP6721568B2 (ja) * 2014-07-29 2020-07-15 セレクティスＣｅｌｌｅｃｔｉｓ がん免疫療法のためのｒｏｒ１（ｎｔｒｋｒ１）特異的キメラ抗原レセプター
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
AU2015310897B2 (en) 2014-09-04 2020-03-19 Cellectis Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
ES2850325T3 (es) 2014-10-09 2021-08-27 Engmab Sarl Anticuerpos biespecíficos contra CD3epsilon y ROR1
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
KR20160132534A (ko) 2015-05-11 2016-11-21 경북대학교병원 ＲＯＲα 활성조절제를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
JP2018524284A (ja) * 2015-05-18 2018-08-30 ユーリカ セラピューティックス， インコーポレイテッド 抗ｒｏｒ１抗体
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
WO2016185035A1 (en) 2015-05-20 2016-11-24 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
JP2019502363A (ja) 2015-10-30 2019-01-31 エヌビーイー セラピューティクス アクチェン ゲゼルシャフト 抗ｒｏｒ１抗体
SG11201806120WA (en) 2016-01-20 2018-08-30 Scripps Research Inst Ror1 antibody compositions and related methods
AU2017289270B2 (en) 2016-06-27 2023-05-04 The Regents Of The University Of California Cancer treatment combinations
CA3030841A1 (en) 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN111587124B (zh) 2017-06-23 2024-01-12 维洛斯生物股份有限公司 Ror1抗体免疫缀合物
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
AU2018315127B2 (en) 2017-08-07 2021-12-23 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
WO2019051135A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
US20210069241A1 (en) 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
US10905750B2 (en) 2017-11-10 2021-02-02 Donald J. Davidson GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
JP2021514631A (ja) 2018-02-26 2021-06-17 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための組成物および方法
WO2019173843A1 (en) * 2018-03-09 2019-09-12 The Regents Of The University Of California Combination treatment of chemoresistant cancers
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EP3831944A4 (en) * 2018-08-01 2021-11-10 National University Corporation Tokai National Higher Education and Research System ANTI-MMR1 MONOCLONAL ANTIBODY, ASSOCIATED FUNCTIONAL FRAGMENT, GENE, COMPOSITION OF DRUG ADMINISTRATION AND PHARMACEUTICAL COMPOSITION
MX2023008176A (es) 2021-03-09 2023-07-18 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Proteina de union a ror1 y uso de la misma.
EP4349372A1 (en) 2021-06-02 2024-04-10 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody drug conjugate, and preparation method therefor and use thereof
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CN113980133B (zh) * 2021-10-29 2022-09-13 叶鑫淼 抗体及其在抗肿瘤中的应用
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
US5169836A (en) 1988-11-10 1992-12-08 Trustees Of The University Of Penna. Inhibitors of platelet binding
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9108652D0 (en) 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
US5843749A (en) 1991-07-26 1998-12-01 Regeneron Pharmaceuticals, Inc. Ehk and Ror tyrosine kinases
ES2130177T3 (es) 1991-08-10 1999-07-01 Medical Res Council Tratamiento de poblaciones de celulas.
US5830470A (en) 1992-09-07 1998-11-03 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5977316A (en) 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
DE69616651D1 (de) 1995-05-26 2001-12-13 Merck Patent Gmbh Antiidiotypische Antikörper die eine Immunantwort gegen den Rezeptor für epidermalen Wachstumsfaktor induzieren
CA2223577A1 (en) 1995-06-07 1996-12-19 Connaught Laboratories Limited Chimeric antibodies for delivery of antigens to selected cells of the immune system
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
EP0918858A1 (en) 1996-05-10 1999-06-02 Biogen, Inc. Common gamma chain blocking agents
JP2000516452A (ja) 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
ES2352082T3 (es) 1997-11-21 2011-02-15 Merck Serono Biodevelopment Polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección.
US7041490B1 (en) 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
US6562958B1 (en) 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
WO2000000619A2 (en) 1998-06-26 2000-01-06 Iowa State University Research Foundation, Inc. MATERIALS AND METHODS FOR THE ALTERATION OF ENZYME AND ACETYL CoA LEVELS IN PLANTS
ES2246093T3 (es) 1998-10-16 2006-02-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Patogenicida molecular que induce una resistencia a la enfermedad en las plantas.
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
CA2366479A1 (en) 1999-03-11 2000-09-14 Genesis Research And Development Corporation Ltd. Compositions and methods for the modification of gene transcription
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US6753314B1 (en) 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
ES2274781T3 (es) 1999-04-13 2007-06-01 Wilex Ag Empleo diagnostico y terapeutico de anticuerpos contra el receptor de la urocinasa.
US20060242729A1 (en) 1999-07-30 2006-10-26 Cahoon Edgar B Polynucleotides encoding proteins involved in plant metabolism
GB9918788D0 (en) 1999-08-10 1999-10-13 Leuven K U Res & Dev Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
DE19946142A1 (de) 1999-09-27 2001-03-29 Bundesrepublik Deutschland Let Gentransfer in humane Lymphocyten mittels retroviraler scFv-Zelltargeting Vektoren
US20020034784A1 (en) 1999-10-27 2002-03-21 John Bertin Novel molecules of the card-related protein family and uses thereof
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
AU2001238677A1 (en) 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
US20030092091A1 (en) 2000-03-07 2003-05-15 Abrahamson Julie A. Sialoadhesin factor-2 antibodies
US6833447B1 (en) 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
US20140072980A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
JP4323167B2 (ja) 2001-01-16 2009-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離
US20140072979A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002256985B8 (en) 2001-01-26 2008-03-20 Inhibitex, Inc Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP1401866A2 (en) 2001-02-22 2004-03-31 Institut Pasteur Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7282336B2 (en) 2001-07-18 2007-10-16 Bionomics Limited Method of diagnosing epilepsy
KR100464926B1 (ko) 2001-09-14 2005-01-05 한국과학기술연구원 ＨＩＶ-1 ｇｐ41의 Ｎ-말단에 특이적으로 결합하는 항체
US7361478B2 (en) 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1495055B1 (en) 2002-04-18 2013-08-14 Genencor International, Inc. Production of functional antibodies in filamentous fungi
GB0210783D0 (en) 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US8344211B2 (en) 2008-08-13 2013-01-01 Ceres, Inc. Plant nucleotide sequences and corresponding polypeptides
US7205450B2 (en) 2003-10-08 2007-04-17 The Regents Of The University Of California DMI1 gene encodes a protein that is required for the early steps of bacterial and fungal symbioses
PE20090047A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
AU2005206536B2 (en) 2004-01-16 2010-09-02 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US7608700B2 (en) 2004-03-08 2009-10-27 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding stress-related proteins and uses therefor
US20080318212A1 (en) 2004-04-06 2008-12-25 Wilson Cindy A Orphan Receptor Tyrosine Kinase as a Target in Breast Cancer
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
PL1765397T3 (pl) 2004-05-25 2013-04-30 Tactic Pharma Llc Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)
US7629444B1 (en) 2004-06-15 2009-12-08 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus bovienii strain Xs85831 and uses thereof
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
US7319142B1 (en) 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CN104829720B (zh) 2005-01-06 2019-01-01 诺和诺德公司 Kir结合剂和使用其的方法
WO2006092449A2 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
US8119385B2 (en) 2005-03-04 2012-02-21 Bp Corporation North America Inc. Nucleic acids and proteins and methods for making and using them
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
US7723110B2 (en) 2005-06-17 2010-05-25 Arborgen, Llc Plant cell signaling genes
WO2007014169A2 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-cd26 antibodies and methods of use thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0520436D0 (en) 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
EP1948680A4 (en) 2005-10-28 2010-01-13 Univ California METHOD AND COMPOUNDS FOR DETECTING AND ISOLATING LYMPHOMA CELLS
WO2008103849A2 (en) 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
CN101360826B (zh) 2005-11-18 2014-04-30 格兰马克药品股份有限公司 抗α2整联蛋白抗体及它们的用途
EP1957541A2 (en) 2005-11-21 2008-08-20 Laboratoires Serono SA Compositions and methods of producing hybrid antigen binding molecules and uses thereof
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK1976880T3 (en) 2005-12-21 2016-09-26 Amgen Res (Munich) Gmbh Pharmaceutical compositions with resistance to soluble cea
KR20140091765A (ko) 2006-01-12 2014-07-22 알렉시온 파마슈티칼스, 인코포레이티드 Ｏｘ-2/ｃｄ200에 대한 항체 및 이들의 용도
CA2821436A1 (en) 2006-02-09 2007-08-16 Pioneer Hi-Bred International, Inc. Genes for enhancing nitrogen utilization efficiency in crop plants
EP2044109B1 (en) 2006-02-10 2014-05-21 Monsanto Technology, LLC Identification and use of target genes for control of plant parasitic nematodes
WO2007103470A2 (en) 2006-03-06 2007-09-13 Medimmune, Inc. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP2009530422A (ja) 2006-03-21 2009-08-27 ウェイバー，デヴィッド，ティー． 抗体のヒト化方法及びそれによって得られるヒト化抗体
US20070286858A1 (en) 2006-03-21 2007-12-13 Wyeth Methods and Compositions for Antagonism of RAGE
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US7727525B2 (en) 2006-05-11 2010-06-01 City Of Hope Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
CN101448951B (zh) 2006-05-19 2013-04-10 泰华制药工业有限公司 融合蛋白、其用途以及制备方法
JP4686634B2 (ja) 2006-06-02 2011-05-25 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
JP2009539413A (ja) 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
EP2047252B1 (en) 2006-06-22 2013-01-23 Walter and Eliza Hall Institute of Medical Research Structure of the insulin receptor ectodomain
WO2008007804A1 (fr) 2006-07-12 2008-01-17 Gene Techno Science Co., Ltd. ANTICORPS ANTI-INTÉGRINE α-9 HUMAINE ET UTILISATION DE CELUI-CI
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
JP2009274958A (ja) 2006-08-31 2009-11-26 Nara Prefecture 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体
ES2902063T3 (es) 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Proteínas de unión a interleucina-13
AU2007312367B2 (en) 2006-10-12 2012-09-06 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
US7935791B2 (en) 2006-12-18 2011-05-03 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
CA2676766A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
CN101951953A (zh) 2007-02-27 2011-01-19 株式会社未来创药研究所 含抗grp78抗体作为有效成分的药物组合物
EP2132229B1 (en) 2007-03-01 2016-05-11 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
WO2008115732A2 (en) 2007-03-20 2008-09-25 Eli Lilly And Company Anti-sclerostin antibodies
US7959916B2 (en) 2007-04-23 2011-06-14 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by ERp5
EP2152750A1 (en) 2007-04-23 2010-02-17 Schering Corporation Anti-mdl-1 antibodies
WO2008137629A2 (en) 2007-05-03 2008-11-13 Regeneron Pharmaceuticals, Inc. Identifying germline competent embryonic stem cells
AU2008282863A1 (en) 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
BRPI0817108B8 (pt) 2007-09-21 2021-05-25 Univ California composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.
EP2220122A2 (en) 2007-11-13 2010-08-25 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against tl1a
US8309323B2 (en) 2007-11-13 2012-11-13 Synthetic Genomics, Inc. Dimethyloctane as an advanced biofuel
US20130338038A1 (en) 2007-12-21 2013-12-19 Pdl Biopharma, Inc. Method of screening complex protein libraries to identify altered properties
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
AU2009251767A1 (en) 2008-02-28 2009-12-03 Battelle Energy Alliance, Llc Thermophilic and thermoacidophilic metabolism genes and enzymes from Alicyclobacillus acidocaldarius and related organisms
CA2715212A1 (en) 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
JPWO2009116491A1 (ja) 2008-03-21 2011-07-21 株式会社林原生物化学研究所 ヒトインターフェロンαサブタイプα８及びその変異蛋白質を特異的に認識するモノクローナル抗体
PE20091674A1 (es) 2008-03-27 2009-11-04 Lilly Co Eli Antagonistas del receptor de glucagon
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
JP2010014691A (ja) 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
EP2316491B1 (en) 2008-07-18 2016-10-12 National University Corporation Nagoya University Cell proliferation inhibitor
NZ590330A (en) 2008-07-21 2012-08-31 Immunomedics Inc Structural variants of anti-cd20 antibodies for improved therapeutic characteristics
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
BR122021014172B1 (pt) 2008-08-18 2022-09-06 Evogene Ltd Método para aumentar a eficiência de uso do nitrogênio, eficiência de uso de fertilizantes, produção, taxa de crescimento, vigor, biomassa e/ou tolerância ao estresse de falta de nitrogênio de uma planta
JP5775458B2 (ja) 2008-11-06 2015-09-09 グレンマーク ファーマシューティカルズ， エセ．アー． 抗α２インテグリン抗体を使用する処置
KR20110110349A (ko) 2009-01-29 2011-10-06 아보트 러보러터리즈 Ｉｌ-1 결합 단백질
EP2810652A3 (en) 2009-03-05 2015-03-11 AbbVie Inc. IL-17 binding proteins
AU2010238723A1 (en) 2009-04-23 2011-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
EP2246364A1 (en) 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
US8753631B2 (en) 2009-05-01 2014-06-17 New York University Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
US8815242B2 (en) 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
EP2462161B1 (en) 2009-08-06 2017-03-08 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP2473530B1 (en) 2009-09-03 2015-04-22 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
TW201122101A (en) 2009-10-28 2011-07-01 Facet Biotech Corp Anti-EGFR antibodies and their uses
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
SG181707A1 (en) 2009-12-18 2012-07-30 Sanofi Sa Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
WO2011079902A2 (en) 2009-12-18 2011-07-07 Biolnvent International Ab Biological materials and uses thereof
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
CN103080307A (zh) 2010-01-25 2013-05-01 美艾利尔斯卡保罗有限公司 A25噬菌体溶解酶
WO2011094259A2 (en) 2010-01-28 2011-08-04 Glaxo Group Limited Cd127 binding proteins
EP2532743B1 (en) 2010-02-04 2015-04-15 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
NZ601580A (en) 2010-02-11 2014-11-28 Alexion Pharma Inc Therapeutic methods using anti-cd200 antibodies
JP5972176B2 (ja) 2010-02-23 2016-08-17 サノフイ 抗アルファ２インテグリン抗体及びそれらの使用
PT2539366T (pt) 2010-02-26 2018-02-13 Bioarctic Neuroscience Ab Anticorpos de ligação a protofibrilas e sua utilização em métodos terapêuticos e diagnósticos para a doença de parkinson, demência com corpos de lewy e outras alfa-sinucleinopatias
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CN102190728B (zh) 2010-03-17 2014-07-02 永卓博济(上海)生物医药技术有限公司 一种人源化抗cd20单克隆抗体
US8468130B2 (en) 2010-04-02 2013-06-18 Skyfire Labs, Inc. Assisted hybrid mobile browser
WO2011137114A1 (en) 2010-04-26 2011-11-03 Abraxis Bioscience, Llc Sparc binding antibodies and uses thereof
NZ629829A (en) 2010-04-30 2015-11-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
CN101928347B (zh) 2010-05-05 2013-03-27 上海海抗中医药科技发展有限公司 抗癌胚抗原抗体及其应用
AU2011261270A1 (en) 2010-06-03 2012-12-13 Abraxis Bioscience, Llc Peripheral blood SPARC antibodies and uses thereof
PT2580240T (pt) 2010-06-14 2019-03-29 Lykera Biomed S A Anticorpos as100a4 e utilizações terapêuticas dos mesmos
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
WO2012012695A2 (en) 2010-07-23 2012-01-26 Fred Hutchinson Cancer Research Center A method for the treatment of obesity
PT2608809T (pt) 2010-08-27 2019-08-26 Gilead Biologics Inc Anticorpos para a metaloproteinase 9 da matriz
PT2918607T (pt) 2010-09-21 2018-01-11 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
RU2013123793A (ru) 2010-11-24 2014-12-27 Лексикон Фармасьютикалз, Инк. Антитела, связывающиеся с notum пектинацетилэстеразой
WO2012075158A1 (en) 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
KR20130133247A (ko) 2010-12-21 2013-12-06 애브비 인코포레이티드 Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
MA34978B1 (fr) 2011-03-30 2014-03-01 Boehringer Ingelheim Int Antidotes pour anticoagulants
CN108578685A (zh) 2011-04-21 2018-09-28 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
JP5944994B2 (ja) 2011-08-12 2016-07-05 オメロス コーポレーション 抗ｆｚｄ１０モノクローナル抗体およびそれらの使用方法
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
EP2776470A2 (en) 2011-11-11 2014-09-17 Rinat Neuroscience Corporation Antibodies specific for trop-2 and their uses
CN112812183A (zh) 2011-11-16 2021-05-18 勃林格殷格翰国际有限公司 抗il-36r抗体
SG11201402619VA (en) 2011-11-23 2014-10-30 Igenica Biotherapeutics Inc Anti-cd98 antibodies and methods of use thereof
WO2013078977A1 (zh) 2011-11-28 2013-06-06 厦门松霖科技有限公司 一种面盖隐藏式花洒
EP2617319A1 (en) 2012-01-17 2013-07-24 Braun GmbH Head portion and handle portion of an oral care device
SI2812443T1 (sl) 2012-02-06 2019-10-30 Inhibrx Inc Protitelesa CD47 in postopki za njihovo uporabo
JP6195855B2 (ja) 2012-03-03 2017-09-13 イミュンジーン，インコーポレーテッド 工学的に作製した抗体−インターフェロン変異体融合分子
US9982249B2 (en) 2012-07-24 2018-05-29 Bp Corporation North America Inc. Xylose isomerases and their uses
CN103792364B (zh) 2012-10-31 2016-06-08 张宝弘 用于检测外周血中循环肿瘤细胞ror1蛋白的试剂及其应用
TWI675044B (zh) 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
JP6739329B2 (ja) 2013-03-14 2020-08-12 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖコア脂質結合ドメインモノクローナル抗体
US9068204B2 (en) 2013-03-15 2015-06-30 The United States Of America, As Represented By The Secretary Of Agriculture Peptidoglycan hydrolase antimicrobials for eradicating lactobacilli that contaminate and reduce ethanol yields in biofuel fermentation
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
BR112016013514B1 (pt) 2013-12-13 2022-04-19 Stora Enso Oyj (Fi) Papelão de múltiplas camadas
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition

Also Published As

Publication number Publication date
EP2663579A2 (en) 2013-11-20
US10900973B2 (en) 2021-01-26
PL2663579T3 (pl) 2017-09-29
US20180348232A1 (en) 2018-12-06
EP3885366A3 (en) 2021-12-29
US20160097776A1 (en) 2016-04-07
US20210208158A1 (en) 2021-07-08
US10627409B2 (en) 2020-04-21
DK3252076T3 (da) 2019-12-02
CA2981662C (en) 2019-02-05
US9523695B2 (en) 2016-12-20
HUE053720T2 (hu) 2021-07-28
EP2663579A4 (en) 2014-09-17
US9217040B2 (en) 2015-12-22
US20170248585A1 (en) 2017-08-31
ES2865068T3 (es) 2021-10-14
WO2012097313A2 (en) 2012-07-19
CA2981662A1 (en) 2013-07-19
CA3027071A1 (en) 2013-07-19
EP3604339B1 (en) 2021-03-10
EP2663579B1 (en) 2017-04-26
EP3252076A1 (en) 2017-12-06
PL3604339T3 (pl) 2021-12-27
WO2012097313A3 (en) 2013-01-10
CA2858350A1 (en) 2013-07-19
US20200309785A1 (en) 2020-10-01
PT3604339T (pt) 2021-04-13
DK3604339T3 (da) 2021-04-12
EP3885366A2 (en) 2021-09-29
ES2758533T3 (es) 2020-05-05
ES2634098T3 (es) 2017-09-26
EP3604339A1 (en) 2020-02-05
US9933434B2 (en) 2018-04-03
HUE035281T2 (en) 2018-05-02
EP3252076B1 (en) 2019-09-04
DK2663579T3 (en) 2017-07-31
US11536727B2 (en) 2022-12-27
US20130273073A1 (en) 2013-10-17
US20230341412A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
HK1255608A1 (zh) 抗htra1抗體及使用方法
HK1199892A1 (en) Modified mini-hepcidin peptides and methods of using thereof
ZA201308022B (en) Anti-cd40 antibodies and methods of use
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
HK1201843A1 (en) Anti-polyubiquitin antibodies and methods of use
EP2771694A4 (en) MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
EP2663647A4 (en) POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
GB201114858D0 (en) Anti-nerve growth factor antibodies and methods of using the same
ZA201400562B (en) Axmi205 variant proteins and methods for their use
EP3210997C0 (en) MEANS AND METHOD FOR EXPRESSING AND SECRETING PEPTIDES AND PROTEINS
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
EP2663330A4 (en) ANTIBODIES TO TLR4 AND METHOD FOR THEIR USE
EP2558496A4 (en) ANTIBODIES TO POLYUBIQUITINE AND METHOD FOR THEIR USE
HK1209432A1 (en) Anti-jagged antibodies and methods of use
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
EP2785742A4 (en) ANTI-KDR ANTIBODIES AND METHOD OF USE THEREOF
EP2670436A4 (en) FOXC1 ANTIBODIES AND METHOD FOR THEIR USE